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Pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of all pancreatic tumours,
is a devastating malignancy with an extremely poor prognosis, as shown by a 1-year survival rate of
around 18% for all stages of the disease. The low survival rates associated with PDAC primarily reﬂect the
fact that tumours progress rapidly with few speciﬁc symptoms and are thus at an advanced stage at
diagnosis in most patients. As a result, there is an urgent need to develop accurate markers of pre-
invasive pancreatic neoplasms in order to facilitate prediction of cancer risk and to help diagnose the
disease at an earlier stage. However, screening for early diagnosis of prostate cancer remains challenging
and identifying a highly accurate, low-cost screening test for early PDAC for use in clinical practice re-
mains an important unmet need. More effective therapies are also crucial in PDAC, since progress in
identifying novel therapies has been hampered by the genetic complexity of the disease and treatment
remains a major challenge. Presently, the greatest step towards improved treatment efﬁcacy has been
made in the ﬁeld of palliative chemotherapy by introducing FOLFIRINOX (folinic acid, 5-ﬂuorouracil,
irinotecan and oxaliplatin) and gemcitabine/nab-paclitaxel. Strategies designed to raise the proﬁle of
PDAC in research and clinical practice are a further requirement in order to ensure the best treatment for
patients. This article proposes a number of approaches that may help to accelerate progress in treating
patients with PDAC, which, in turn, may be expected to improve the quality of life and survival for those
suffering from this devastating disease.
Copyright © 2014, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All
rights reserved.Introduction
Pancreatic ductal adenocarcinoma (PDAC), the most frequent
form of pancreatic cancer, is a common malignancy, with around
280,000 newcases being diagnosedworldwide in 2008, and 70,000
cases seen in the European Union alone [1]. Although PDAC is the
twelfth most common cancer worldwide, its low survival rategaciones Oncologicas (CNIO),
34 91 224 6931.
by Elsevier India, a division of Remeans that it is the fourth leading cause of cancer-related death in
Western countries [1e3]. Indeed, this tumour is associated with an
extremely poor prognosis, as shown by a 1-year survival rate of
around 18% for all stages of the disease, falling to less than 4% at 5
years [2]. The low survival rates associated with PDAC primarily
reﬂect the fact that tumours progress rapidly with few speciﬁc
symptoms and are thus at an advanced stage at diagnosis, with only
10% being operable. Therefore, it is not possible to survive PDAC in
the way that colorectal or breast cancer can be survived [4].
While earlier diagnosis of the disease is clearly required to
improve outcomes, more effective therapies are also urgentlyed Elsevier India Pvt. Ltd. All rights reserved.
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hampered by the genetic complexity of the disease and the lack of
prognostic markers, underlining the need for new treatment
approaches.
Pathogenesis of pancreatic cancer
PDAC accounts for more than 90% of all pancreatic tumours,
which constitute a heterogeneous set of diseases encompassing
cancers of the endocrine and exocrine pancreas. Genetic studies
suggest that PDAC develops from one of three known precursor
lesions e pancreatic intraepithelial neoplasias (PanINs), intraductal
papillary mucinous neoplasms and mucinous cystic neoplasms e
though the majority develop from PanINs, progressing from PanIN-
1A and -1B through to PanIN-3 [5e7]. There is, however, some
debate regarding the PanIN progression model [8,9]. Whole-exome
sequencing studies have established that different precursor le-
sions are associated with distinct genetic alterations that mirror
their histological progression (Table 1) [6,7]. Further studies into
the genetic features of these initial lesions may provide an oppor-
tunity for early diagnosis of the disease while it is still in the
curative stage. Genetic data have been interpreted to suggest that
development of invasive disease from these precursor lesions oc-
curs over a considerable length of time (17 years on average), with
death following after 2e3 years, highlighting the importance of
identifying early diagnostic markers [10e12]. Although the un-
availability of early-stage tissue from patients with non-invasive
precursor lesions has hampered the search for such markers, use
of pancreatic cancer mouse models is likely to go some way to
further the understanding of tumour initiation and progression
[13,14]. Indeed, human PDAC xenografts and genetically-
engineered mouse models have already been used to demon-
strate the potential for the use of elevated Cath E (a protease highly
and speciﬁcally expressed in PDAC) in PDAC and PanIN as an
imageable, early biomarker for pancreatic cancer [15]. Neverthe-
less, screening for early diagnosis of pancreatic cancer remains
challenging due to the low incidence of the disease, requiring a
highly speciﬁc and sensitive test [16]. While focussing efforts on
high-risk groups comprising those with a syndromic or familial risk
of PDAC may improve accuracy, these groups represent only a mi-
nority of affected individuals [17e19]. Consequently, identifying an
accurate, low-cost screening test for early PDAC for use in clinical
practice remains an important unmet need. Given the cost to so-
ciety, future research efforts are also likely to focus on identifying
possible cancer preventative strategies. In the case of PDAC, risk
factors for the disease have yet to be determined. However, the
recent discovery that oncogenic K-Ras (found in almost allTable 1
Selected somatic alterations in pancreatic ductal adenocarcinoma precursor lesions.
Reproduced with permission from Macgregor-Das et al., 2013 [6].
Gene Genetic
alteration
Pathway or
regulatory process
Altered in
PanINs
Altered in
IPMNs
Altered
in MCNs
KRAS2 Activating GTPase-dependent
signalling
Yes Yes Yes
CDKN2A Inactivating Cell cycle regulation Yes
TP53 Inactivating DNA damage response Yes Yes Yes
SMAD4 Inactivating TGF-b signalling Yes Yes Yes
ARID1A Inactivating Chromatin remodelling Yes
MLL3 Inactivating Chromatin remodelling Yes
GNAS Activating G protein-mediated
signalling
No Yes
RNF43 Inactivating Ubiquitin-dependent
protein degradation
No Yes Yes
PanIN: pancreatic intraepithelial neoplasia; IPMN: intraductal papillary mucinous
neoplasm; MCN: mucinous cystic neoplasm.pancreatic cancers) is not constitutively active as previously
thought, but requires activation by upstream stimulants [20], pre-
sents exciting possibilities for future prevention strategies. Since a
large number of healthy individuals harbour Ras mutations [21],
interventions aimed at reducing Ras activation is likely to have
important cancer-preventive value, particularly in those with
oncogenic Ras mutations [20].
Several core signalling pathways have been found to be genet-
ically altered in PDAC, including apoptosis and Hedgehog, trans-
forming growth factor-b (TGF-b) and KRAS signalling, with tumours
containing an average of 63 alterations (Fig. 1) [22]. Key genes
mutated in the majority of PDAC tumours include KRAS, TP53,
SMAD4 and CDKN2A [22,23]. KRAS is an early mutation occurring in
PanIN-1A lesions, suggesting that this alteration may play an
important role in the initiation of many PDACs [6,24]. Mutations of
CDKN2A and TP53 are also known to be involved in PDAC patho-
genesis and their inactivation has been observed in around 80% and
50% of tumours, respectively [25,26]. SMAD4 inactivation is a late
event present in 50e60% of tumours and may be associated with
more aggressive disease [27,28]. Although the complex signalling
pathways underlying the development of PDAC have yet to be fully
elucidated, genomic analysis of large cohorts of patients can be
used to identify common mechanisms and will be key to the
development of novel therapeutic strategies for the disease [23].
The tumour microenvironment may also present an opportunity
for therapeutic targeting since extensive stromal cross-talk occurs
with tumour cells, with stromaleepithelial interactions contrib-
uting to tumour spread and metastases [29]. However, recent
studies involving elimination of stroma-promoting Hedgehog sig-
nalling in mouse models of PDAC indicate that the role of the
stroma in PDAC progression is not straight-forward, with some
stromal components acting to restrain tumour growth [30]. Further
studies are needed, therefore, in order to clarify the value of the
stroma as a therapeutic target in PDAC. Additional research is also
needed into the role of cancer stem cells (CSCs) in PDAC, since
available studies suggest that a small population of these cells may
be responsible for tumour initiation and propagation [31,32].Fig. 1. Core signalling pathways and processes genetically altered in the majority of
pancreatic cancers [22].
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chemotherapy and radiotherapy, suggesting that new therapies
that speciﬁcally target these cells are necessary in order to improve
outcomes.
Current treatment options and unmet needs in resectable and
locally advanced pancreatic cancer
Survival rates for patients with PDAC are extremely poor, pri-
marily due to themajority of tumours being at an advanced stage at
diagnosis (Fig. 2) [33]. Indeed, only 10% of cases are resectable at
presentation and more than 90% of patients undergoing potentially
curative resection still die of the disease due to local recurrence
and/or distant metastases in the absence of adjuvant therapy. There
is a developing consensus on the deﬁnitions of an R0, R1 and R2
resection, permitting better comparison between studies [34,35].
Using a systematic approach to examining the resected specimen in
the clinical pathology laboratory, a macroscopically clear resection
is deﬁned as R0 if there are no tumour cells within 1 mm of any
surface, R1 if one or more tumour cells are visible within 1 mm of
any surface and R2 where the resection is macroscopically incom-
plete. Using this deﬁnition, around 70% of macroscopically clear
resections are actually R1 resections [34,35]. Nevertheless, it is
apparent that survival in patients with an R0 resection is only
marginally longer than in those with an R1 resection provided
adjuvant chemotherapy is used [36e38].
The high rate of recurrence in PDAC is mostly caused by occult
primary metastases, but may also be a result of microscopically
incomplete resection and other biological features of the tumour
such as frequent neural invasion [39], highlighting the importance
of specialized surgeons and pathologists in the treatment of this
condition. Accurate selection of the patients who are eligible for
macroscopic (R0 or R1) resection with adjuvant chemotherapy is
also vital, since median survival following incomplete macroscopic
surgical resection (R2) of the primary tumour is comparable to that
of patients with inoperable locally advanced disease treated with
chemotherapy [34e38,40e42]. There is also a growing consensus
on the radiological deﬁnitions of ‘resectable’, ‘borderline resectable’
and ‘unresectable’, and the National Comprehensive Cancer
Network in the USA has endorsed a modiﬁed consensus from the
Americas Hepato-Pancreato-Biliary Association, the Society ofFig. 2. Summary of survival and resection percentages for patients with pancreatic cancer
treatment; Pall.: palliative; Adj.: adjuvant.Surgical Oncology and the Society for Surgery of the Alimentary
Tract [43,44].
Current imaging modalities used for preoperative staging
include abdominal ultrasound, computed tomography, magnetic
resonance imaging and endoscopic ultrasonography. Of these,
computed tomography may be the best means of assessing
resectability initially based on vascular involvement, while endo-
scopic ultrasonography has the ability to detect small lesions and
may be optimal for the diagnosis of PDAC in subjects with non-
speciﬁc ﬁndings on conventional imaging [45]. Endoscopic ultra-
sonography combined with ﬁne needle aspiration or needle biopsy
is also becoming essential in order to obtain tumour samples for
determination of the biomolecular proﬁle that will drive outcome
and treatment response [46]. Other techniques under investigation
include multi-parametric imaging and functional and molecular
markers. Functional markers currently being studied as indicators
of disease progression include stromal changes, microvascular
density and tumour metabolism [47,48]. CXCR4 is the only molec-
ular candidate to date to correlate with rapid and metastatic pro-
gression, while for SMAD4, current data are not robust enough for
identiﬁcation of a locoregional recurrence pattern [49].
The poor survival rate associated with surgery alone for early-
stage PDAC has led to adjuvant therapy becoming the standard of
care after resection in an effort to prolong survival (Table 2)
[36e38,40,50e60]. Approaches differ between Europe, where
gemcitabine-based chemotherapy tends to be the standard adju-
vant therapy, and the USA, where both ﬂuoropyrimidine-based
chemoradiotherapy and chemotherapy (preferentially with gem-
citabine) are accepted standards. While meta-analyses of data from
randomized controlled trials have shown a disease-free survival
and overall survival beneﬁt for adjuvant chemotherapy [61,62], the
role of adjuvant chemoradiation is not established, with mounting
evidence being non-supportive of its use [36,40,55,63,64]. Adjuvant
gemcitabine does not result in longer survival than adjuvant 5-
ﬂuorouracil (5-FU) [30,46], and a 5-FU prodrug combination (S-1)
has recently been shown in a study from Japan to greatly increase
survival over gemcitabine [38]. The S-1 oral preparation combines
tegafur (the 5-FU prodrug) with gimeracil (an inhibitor of dihy-
dropyrimidine dehydrogenase that otherwise degrades 5-FU) and
oteracil, which helps to reduce gastrointestinal-related toxicity by
inhibiting 5-FU phosphorylation within the gastrointestinal lumen.. Reproduced with permission from Gillen et al., 2010 [33]. Neoadj.: neoadjuvant; Tx:
Table 2
Randomized controlled trials of adjuvant therapy in patients with resectable pancreatic cancer.
Study Treatment N Median survival
(months)
Five-year survival
(%)
Neoptolemos et al., 2001 [40] Surgery þ CRT (bolus 5-FU þ EBRT) 175 15.5 NR
Surgery þ No CRT 178 16.1 (p ¼ 0.235) NR
Takada et al., 2002 [50] Surgery 77 NR 18
Surgery þ CT (MF) 81 NR (NS; p value NR) 11.5
Neoptolemos et al., 2004 [36] Surgery 144 17.9 20
vs.
Surgery þ CRT (bolus 5-FU þ EBRT) 145 15.9 (p ¼ 0.05) 10
Surgery 142 15.5 8
vs.
Surgery þ CT (5-FU, 6 cycles) 147 20.1 (p ¼ 0.009) 21
Kosuge et al., 2006 [51] Surgery 44 15.8 14.9
Surgery þ CT (cisplatin/5-FU, only 2 cycles) 45 12.5 (p ¼ 0.94) 26.4
Regine et al., 2008 [52] Surgery þ CT (5-FU, 1 cycle) þ CRT (5-FU þ EBRT) þ CT (5-FU, 3 cycles) 230 17 NR
Surgery þ CT (gemcitabine, 1 cycle) þ CRT (5-FU þ EBRT) þ CT
(gemcitabine, 3 cycles)
221 19 (p ¼ 0.34) NR
Neoptolemos et al., 2009 [53] Surgery 225 16.8 NR
Surgery þ CT (5-FU, 6 cycles) 233 23.2 (p ¼ 0.003) NR
Ueno et al., 2009 [54] Surgery 60 18.4 NR
Surgery þ CT (gemcitabine, 3 cycles) 58 22.3 (p ¼ 0.29) NR
Van Laethem et al., 2010 [55] Surgery þ CT (gemcitabine, 4 cycles) 45 24.4 NR
Surgery þ CT (gemcitabine, 2 cycles) þ CRT (gemcitabine þ EBRT) 45 24.3 (NS; p value NR) NR
Neoptolemos et al., 2010 [37] Surgery þ CT (5-FU, 6 cycles) 551 23.0 16.6
Surgery þ CT (gemcitabine, 6 cycles) 537 23.6 (p ¼ 0.94) 19.2
Uesaka et al., 2012 [56] Surgery þ CT (gemcitabine, 6 cycles) 193 11.2 NR
Surgery þ CT (S-1, 4 cycles) 192 23.2 (p < 0.0001) NR
Oettle et al., 2013 [57] Surgery 175 20.2 12.2
Surgery þ CT (gemcitabine, 6 cycles) 179 22.8 (p ¼ 0.01) 20.7
Fukutomi et al., 2013 [38] Surgery þ CT (gemcitabine, 6 cycles, 24 weeks) 191 25.5 NR
Surgery þ CT (S-1, 4 cycles, 24 weeks) 187 46.3 (p < 0.0001) NR
CRT: chemoradiotherapy; 5-FU: 5-ﬂuorouracil; EBRT: external beam radiotherapy; NR: not reported; CT: chemotherapy; MF: mitomycin C followed by 5-FU; NS: not sig-
niﬁcant; S-1: 5-FU prodrug combination (tegafur, gimeracil and oteracil).
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adjuvant chemotherapy as a more important prognostic factor than
early start of chemotherapy; a modest delay of the start of treat-
ment until adequate recovery from surgery has taken place may
increase compliance in some patients and thus prevent treatment
discontinuation [65].
The early metastasizing nature of pancreatic cancer [66], along
with the large proportion of patients presenting with locally
advanced disease and the high frequency of microscopic incom-
plete resections [34,35], provides a strong rationale for neoadjuvant
systemic therapy [66]. Review of the limited evidence suggests that
neoadjuvant therapy does not confer a survival advantage over
resection followed by adjuvant therapy for those with initially
resectable tumours [33]. This is not surprising given the low
effectiveness of the systemic therapy used at that time. Neverthe-
less, neoadjuvant approaches employing increasingly active
chemotherapeutic regimens in metastatic PDAC (e.g. FOLFIRINOX
[folinic acid, 5-FU, irinotecan and oxaliplatin], gemcitabine plus
nab-paclitaxel and/or chemoradiotherapy) may allow downstaging
of borderline resectable disease and some locally advanced cases,
improving R0 resection and survival [67]. Prospective randomized
studies will be required to deﬁne the potential beneﬁt of this
approach [67e70]. For those with unresectable locally advanced
disease, treatment options include FOLFIRINOX, gemcitabine-based
chemotherapy or chemoradiotherapy [71e77]. While chemo-
radiotherapy results in longer survival in patients with locally
advanced PDAC compared with radiation alone or no treatment, it
does not provide longer survival than systemic chemotherapy alone
and increases toxicity [63,64,71,72,75,77]. Recent data from the LAP
07 study also indicate that after induction chemotherapy, further
treatment with chemoradiotherapy has no beneﬁt over continua-
tion of chemotherapy alone in patients with locally advanced
PDAC [77].Challenges in the treatment of metastatic disease
For patients with metastatic PDAC, the primary goals of treat-
ment are palliation and improved survival, yet effective treatments
for this population are limited, leading to extremely poor survival
rates (5e9 months) [33]. Gemcitabine has been the standard
treatment for metastatic disease, primarily due to its effect on
symptoms and favourable toxicity proﬁle rather than a signiﬁcant
effect on survival [73]. However, the combination of gemcitabine
with other agents such as platinum analogues or capecitabine have
not resulted in a substantive improvement, though a combination
of gemcitabine and oxaliplatin may confer an additional but small
survival beneﬁt in patients with good performance status and a
younger age (Table 3) [78e90]. In the UK, gemcitabine plus cape-
citabine is a standard of care for patients with metastatic as well as
locally advanced disease [72,90,91]. FOLFIRINOX has been shown in
a recent phase III study to result in longer survival compared with
gemcitabine (11.1 vs. 6.8 months, respectively) as well as delaying
deterioration of quality of life [69]. Additionally, a combination of
gemcitabine with nab-paclitaxel improved overall survival versus
gemcitabine alone in the phase III Metastatic Pancreatic Adenocar-
cinoma Clinical Trial (MPACT) (8.5 vs. 6.7 months, respectively) [70].
It should be noted, however, that the patient groups included in
these trials (relatively younger patients with good performance
status [0 or 1], limited volume of disease, no biliary obstruction and
a relatively low proportion with pancreatic head tumours) may not
be entirely representative of the patient population encountered in
routine clinical practice. Furthermore, both the FOLFIRINOX and
gemcitabine with nab-paclitaxel regimens are more toxic than
gemcitabine alone, which may limit their use to relatively younger
patients with good performance status [69,70]. Gemcitabine alone
remains a standard treatment for elderly patients [92] or thosewith
poor performance and nutritional status; appropriate identiﬁcation
Table 3
Randomized trials comparing gemcitabine with the combination of gemcitabine plus a platinum analogue or a ﬂuoropyrimidine as ﬁrst-line therapy in patients with met-
astatic pancreatic cancer.
Study Treatment N ORR (%) Median PFS/TTP
(months)
Median survival
(months)
Gemcitabine vs. gemcitabine plus a platinum analogue
Colucci et al., 2002 [78] Gemcitabine
Gemcitabine þ cisplatin
54
53
9.2
26.4 (p ¼ 0.02)
2.0
5.0 (p ¼ 0.048)
5.0
7.5
Viret et al., 2004 [79] Gemcitabine
Gemcitabine þ cisplatin
41
42
5
7
2.5
2.2 (NS; p value NR)
6.7
8.0 (p ¼ 0.73)
Louvet et al., 2005 [80] Gemcitabine
Gemcitabine (FDR) þ oxaliplatin
156
157
17.6
26.8 (p ¼ 0.048)
3.7
5.8 (p ¼ 0.04)
7.1
9.0
Heinemann et al., 2006 [81] Gemcitabine
Gemcitabine þ cisplatin
95
95
8.2
10.2
3.1
5.3 (p ¼ 0.053)
6.0
7.5 (p ¼ 0.15)
Poplin et al., 2009 [82] Gemcitabine
Gemcitabine (FDR)
Gemcitabine (FDR) þ oxaliplatin
275
277
272
6
10.4
9.4
2.6 (p ¼ 0.09)
3.7
2.7
4.9 (p ¼ 0.015)
6.2
5.7
Colucci et al., 2010 [83] Gemcitabine
Gemcitabine þ cisplatin
199
201
10.1
12.9
3.9
3.8 (p ¼ 0.8)
8.3
7.2 (p ¼ 0.38)
Inal et al., 2012 [84] Gemcitabine
Gemcitabine þ cisplatin
156
250
NR 8.9
6.0 (p ¼ 0.08)
12.0
10.5 (p > 0.05)
Gemcitabine vs. gemcitabine plus a ﬂuoropyrimidine
Berlin et al., 2002 [85] Gemcitabine
Gemcitabine þ 5-FU (bolus)
162
160
5.6
6.9
2.2
3.4 (p ¼ 0.22) 5.46.7 (p ¼ 0.09)
Scheithauer et al., 2003 [86] Gemcitabine
Gemcitabine þ capecitabine
42
41
14
17
4.0
2.1 (NS; p value NR)
8.2
9.5 (NS; p value NR)
Riess et al., 2005 [87] Gemcitabine
Gemcitabine þ 5-FU (infusional)
238
235
7.2
4.8
3.5 (p ¼ 0.44)
3.5
6.2 (p ¼ 0.68)
5.9
Di Costanzo et al., 2005 [88] Gemcitabine
Gemcitabine þ 5-FU (continuous infusion)
48
43
8
11
3.5
4.5
7.8
7.5
Herrmann et al., 2005 [89] Gemcitabine
Gemcitabine þ capecitabine
159
160
7.9
10.1
4.0 (p ¼ 0.207)
4.8
7.3 (p ¼ 0.314)
8.4
Cunningham et al., 2009 [90] Gemcitabine
Gemcitabine þ capecitabine
266
267
12.4
19.1 (p ¼ 0.034)
3.8
5.3 (p ¼ 0.004)
6.2
7.1 (p ¼ 0.08)
ORR: objective response rate; PFS: progression-free survival; TTP: time to progression; NS: not signiﬁcant; NR: not reported; FDR: ﬁxed dose rate; 5-FU: 5-ﬂuorouracil.
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necessary toxicity.
The combination of gemcitabine and the epidermal growth
factor receptor (EGFR) inhibitor erlotinib has been approved for the
treatment of metastatic disease by the US Food and Drug Admin-
istration and the European Medicines Agency following demon-
stration of a minimal survival beneﬁt (6.24 vs. 5.91 months for
gemcitabine) in a phase III trial [93]. However, the role of erlotinib
in PDAC has been called into question due to its low clinical activity.
In addition, its beneﬁt only appears to be clinically relevant in those
who develop skin rash. Increasing the dose of erlotinib until the
rash occurs does not appear to be beneﬁcial since the strategy in-
creases toxicity but not survival. Since erlotinib-induced rash is
apparent during the ﬁrst 8 weeks of treatment, however, it may be
possible for patients withmetastatic disease to receive gemcitabine
plus erlotinib, with erlotinib continuing beyond 8 weeks only in
those who develop the rash [73], though these contentions require
additional evidence. Although the results of initial trials with
erlotinib in unselected populations have been disappointing [93],
the agent may be useful in KRAS-mutant p53 wild-type tumours
(~15% of patients), but again prospective evidence is lacking.
Between 40% and 50% of patients with metastatic PDAC receive
second-line treatment after disease progression, generally those
responding to ﬁrst-line therapywho have good performance status.
While the optimal therapy in this setting has not been established
[73], clinical activity has been reported with the combination of 5-
FU and oxaliplatin and also with FOLFIRI (5-FU, irinotecan and
leucovorin) [94e96]. Gemcitabine monotherapy is also reported to
be an effective second-line treatment and may be useful for pa-
tients who have received ﬁrst-line FOLFIRINOX [95]. In each case,
optimal treatment selection for patients with metastatic disease
should take into account their age and performance status, since
combination therapy has no beneﬁt for those with a performancestatus 2 [91,92]. Nutritional support is a further important issue
for such patients as it improves treatment adherence, possibly
leading to improved quality of life and better outcomes. Patients
with locally advanced tumours [97], as well as those who have had
resection for tumours in the head of the pancreas, have reduced
exocrine function and beneﬁt from pancreatic enzyme supple-
mentation [98]. Further randomized trials are needed in order to
deﬁne the best therapy for elderly patients and for those with poor
performance status or nutritional status.
New targets for drug treatment and the promise of
biomarkers in pancreatic cancer
PDAC is genetically very complex with a high diversity of mu-
tations compared with other cancers; however, most alterations
occur with very low frequency and so are challenging to exploit
therapeutically. Furthermore, while KRAS, p16, TP53 and SMAD4 are
the most commonly mutated genes in PDAC [6,22,23,28,99], no
effective inhibitors of these targets have been identiﬁed to date.
Nevertheless, a number of new targets are currently being inves-
tigated including genes associated with chromatin remodelling,
DNA damage repair (e.g. BRACA1 and BRACA2) and mutated axon
guidance (e.g. ROBO3 and ROBO1/2) [23,100]. The results of research
with KRAS-driven PDAC mouse models support an important role
for EGFR early during PDAC progression [101e103]. Preclinical
studies suggest a role for phosphoinositide 3-kinase (PI3K) in-
hibitors in PDAC [104], with consideration being given to the pos-
sibility of combining PI3K inhibitors with other targeted therapies
(e.g. MEK or AKT inhibitors), though toxicity may be an issue with
this approach [105]. CSCs are also being investigated as a potential
target in PDAC due to their putative involvement in resistance and
metastases [106]. Since current chemotherapeutic agents appear to
be largely ineffective at depleting the CSC pool, their combination
M. Hidalgo et al. / Pancreatology 15 (2015) 8e18 13with a CSC-targeted agent may promote tumour regression. This
strategy has already shown promise in preclinical models, with the
combination of gemcitabine and tigatuzumab (an agonist of death
receptor 5, which is enriched in pancreatic CSCs) shown to be more
effective in killing both CSCs and bulk tumour cells than gemcita-
bine alone [106].
A further factor that may contribute to the failure of systemic
therapy in PDAC is the abundant stromal content and poor blood
supply associated with the disease. Moreover, it has been suggested
that the tumour microenvironment may act as a pharmacological
barrier, raising the possibility that it could be a therapeutic target
[107,108]. A number of strategies are being investigated to target
the tumour stroma and vasculature, including inhibition of TGF-b,
which plays a key role in stroma formation, the Notch/Hedgehog
pathway and use of pegylated hyaluronidase to decrease intra-
tumoural pressure and increase vascularization, though phase II
trials with the latter were halted due to unexpected adverse events
[107,109,110]. Secreted protein acidic and rich in cysteine (SPARC) is
a further means of targeting the stroma in PDAC since it is over-
expressed by ﬁbroblasts in the tumour microenvironment and is
inversely correlated with survival [111,112]. Nevertheless, as noted
earlier, further research is required to clarify the potential of the
stroma as a therapeutic target. The concept of a stromal barrier is
also controversial, with a number of studies reporting that systemic
drugs such as gemcitabine and larger agents are able to enter PDAC
in genetically engineered mouse models of the disease [15,113],
suggesting that entry of drugs into pancreatic tumoursmay not be a
major obstacle for therapeutics.
Progress in identifying novel agents for new targets in PDAC
could be accelerated by more appropriate trial design [114]. In
particular, trial designs should be modiﬁed according to disease
stage, with molecular imaging and repeat biopsy used to monitor
disease progression (Fig. 3) [114]. In addition, there must be
increased efforts to understand the molecular effects of novel
drugs prior to clinical testing, with animal models such as patient-
derived xenografts and genetically engineered mouse models
used to screen novel drugs targeting rare mutations. The devel-
opment of biomarkers that predict response to these novel agents
is also crucial, though any potential markers should be evaluated
carefully to ensure effective development, with validationFig. 3. Potential clinical trial designs in pancreatic cancer. Reproduced with permission fro
advanced disease. After a tumour biopsy with or without molecular imaging, patients are ra
second tumour biopsy and appropriate imaging. Patients then proceed to receive ﬁrst-line tre
of molecularly active drugs to be further developed. (B) Trial design to test anticancer stem
disease, such as in the adjuvant setting, rather than in stage IV disease. (C) Clinical trial desig
patients with locally advanced disease this represents an ideal clinical scenario in which to
survival; RR: response rate.undertaken according to the REporting recommendations for
tumour MARKer prognostic studies (REMARK) guidelines
[115,116]. Further aspects that must be taken into account in
biomarker development include factors associated with the drug
itself, as well as its impact on the stroma and target cell. Drug
levels should ideally be examined in both the tumour and blood,
with germ cell single nucleotide polymorphisms (SNPs) that affect
drug metabolism being considered as they can determine drug
response. Stromal factors to be taken into account include the
roles played by vascularity, lymphatic density, stromal volume
and inﬂammatory inﬁltrate. With respect to the target cell, con-
siderations include drug uptake and export, activation and inac-
tivation, drugedrug interaction and other contingent factors,
including genetic mutations and protein and microRNA
expression.
The range of different approaches employed for biomarker
discovery (e.g. Luminex multiplex technology and transcriptomic
analysis) have yet to produce a biomarker used in clinical practice,
though a number of promising possibilities are on the horizon. One
of these biomarkers, the human equilibrative nuclear transporter
type-1 (hENT1), is important for the transport of gemcitabine into
and out of PDAC cells [117], and may be useful for selecting patients
who would better respond to either gemcitabine- or 5-FU-based
adjuvant regimens [118e120]. So far, the predictive value of hENT1
has only been shown in the setting of adjuvant therapy, while
hENT1 expression was not associated with efﬁcacy of gemcitabine
applied for palliative treatment [121]; however, expression in this
latter study was quantiﬁed using a different anti-hENT1 antibody
from that in the adjuvant studies [118e120]. Before incorporation
of hENT1 determination into clinical practice, problems associated
with methodological aspects need to be resolved, particularly
elucidation of the optimal anti-hENT1 antibody [120]. SPARC
expression has also been proposed to correlate with increased
survival in patients treated with nab-paclitaxel in a phase I/II trial
[122]. However, most recent data from an evaluation of the phase III
MPACT study support the notion that SPARC expression in the
stroma does not serve as a predictor of treatment efﬁcacy in pa-
tients receiving the combination of gemcitabine and nab-paclitaxel
[123]. Clearly, more research is required to understand the true role
of SPARC in this context.m Hidalgo and Von Hoff 2012 [114]. (A) Screening trial of new agents in patients with
ndomized to receive one of several new agents for a short period of time followed by a
atment. Analysis of paired tumour biopsies and molecular imaging allows the selection
cell therapeutics. These agents are more likely to be effective in situations of minimal
n for drugs targeting the cancer stroma. Due to the preponderance of tumour stroma in
test stroma-modulating drugs. Bx: biopsy; CSC: cancer stem cell; PFS: progression-free
M. Hidalgo et al. / Pancreatology 15 (2015) 8e1814To increase the identiﬁcation of novel biomarkers, blood and
tissue samples should be collected from all patients in clinical trials.
This practice is already being performed routinely in trials con-
ducted by the European Study Group for Pancreatic Cancer (ESPAC)
[36,37,40,124], which has accumulated a wealth of samples for
future analysis and provides an excellent resource for future studies
of the disease.New approaches in drug development
The lack of effective therapies and predictive markers for PDAC
has resulted in very poor survival rates for this devastating disease.
Furthermore, despite being the fourth leading cause of cancer-
related death, PDAC receives limited attention and research fund-
ing, and spending on it lags behind that on other cancers. Although
the biology of PDAC has been well studied, progress in identifying
new molecular targets has been slow and few candidate therapies
are registered for the disease, possibly due to its genetic complexity
and histological make-up [22,125]. However, opportunities exist for
exploiting cellular therapeutic targets in PDAC including the
stroma, immune system, blood vessels and cell division. The stroma
in particular is a key target, since tumourestroma interactions have
been implicated in cancer cell invasion and metastases and
contribute to chemoresistance [117,118]. The quest for more effec-
tive therapies for PDAC has also led to research into various
immunotherapeutic strategies in an effort to reprogramme the
immune system to enable more effective detection and destruction
of pancreatic tumour cells. Potential immune therapies include T-
cell, DNA or RNA vaccination, anti-CD40 agents, antibodies against
programmed cell death protein 1 (PD1) and cytotoxic T-lymphocyte
associated antigen-4 binding, and strategies aimed at targetingTable 4
Challenges in pancreatic cancer management in Europe and strategies for addressing th
Challenge
Management of patients with PDAC differs widely across Europe:
 Platinum compounds are still used in some countries despite the lack of
evidence supporting their use
 Attitudes towards second-line therapy vary
 Use of radiotherapy varies between countries for patients with similar
clinical presentations
Treatment is dependent on the national setting and on the organization of oncology,
surgery and radiotherapy services:
 Molecular biological techniques are not available in all centres
 Experienced radiologists are required for accurate staging
 Some chemotherapy regimens require strict monitoring to avoid toxicity
Access and funding for clinical trials is limited and varies between counties
The majority of patients are not diagnosed with PDAC until they have advanced or me
disease; end of life is generally characterized by severe symptoms and poor quality
The molecular biology of PDAC has been well studied but has resulted in few effective
targeted therapies
PDAC: pancreatic ductal adenocarcinoma; REMARK: REporting recommendations for tumTGF-b [126e130]. TGF-b is not only associated with stroma devel-
opment [131], but is also responsible for a profound immunosup-
pression that is characteristic of PDAC [132]. Overcoming this
immune suppression is an important challenge to be taken into
account in the development of novel agents for the treatment of the
disease [39]. Multi-targeted agents inhibiting the stroma, kinases
and apoptosis, such as genistein, are also being investigated [133].
Opportunities for personalized medicine have begun to emerge
in PDAC as a result of advances in the knowledge of PDAC biology.
The importance of SMAD4 in PDAC pathogenesis has been recog-
nized for many years and SMAD4 gene status of the primary car-
cinoma has been shown to correlate with distinct patterns of
treatment failure in patients with the disease [28,134]. Further-
more, response to irinotecan has been shown to differ in SMAD4
mutant and wild-type cancer cells, raising the possibility of
personalized chemotherapy for future patients with PDAC [135].
The availability of whole genome sequencing also allows rare mu-
tations to be identiﬁed in individual patients and targeted specif-
ically, offering further potential for personalized medicine.
However, a more structured approach to the application of this
technology is needed in the future in order to maximize its
potential.Strategies for improving pancreatic cancer outcomes across
Europe
There has been little progress in improving outcomes in PDAC
over the past 30 years and mortality rates closely match incidence,
leading to a mortality incidence ratio of 0.98 [136]. One of the
problems contributing to the limited advances in PDAC is the
complex nature of the disease, with each tumour cell carrying anem.
Strategy for addressing it
 Standardization of management across the region
 Treatment selection based on evidence-based national and
international guidelines
 Harmonization of treatment guidelines in order to have a rational
approach to management
 Randomized controlled trials using a standardized protocol for
pancreatic specimen examination for ease of comparison
between studies
 Referral of patients to specialist centres with surgical expertise
 Management of patients within multidisciplinary teams
comprising experts in surgery, radiotherapy, chemotherapy,
molecular biology and staging
 Development of PDAC networks to improve access to trials and
to coordinate collaboration between healthcare professionals and
industry to improve outcomes
 Cooperation between industry and academia to:
B Ensure that trials are relevant to clinical practice
B Improve access to newly registered drugs (e.g. nab-paclitaxel)
tastatic
of life
 Early introduction of palliative care alongside chemotherapy to
improve quality of life, mood and outcomes
 Identiﬁcation of sensitive and speciﬁc biomarkers to improve
diagnosis of the disease, with prospective markers validated
according to REMARK guidelines
 Employment of alternative strategies involving cellular therapeutic
targets including the stroma, immune system, blood vessels and
cell division
 Use of personalized medicine approaches involving SMAD4 gene
status or whole genome sequencing to identify rare mutations
 Use of PDAC mouse models to improve the understanding of
tumour initiation and progression
our MARKer prognostic studies.
M. Hidalgo et al. / Pancreatology 15 (2015) 8e18 15average of 63 mutations [22]. However, while the need for molec-
ular characterization of different cancers is well recognized and has
been highlighted by the American Society for Clinical Oncology as a
key factor for accelerating progress in cancer [137], the organiza-
tion and society in general have paid little attention to PDAC to
date. Strategies designed to raise the proﬁle of PDAC, in both
research and clinical practice, are thus urgently needed in order to
ensure the best treatment for patients. Given the increasing life
expectancy of many populations worldwide, the incidence of PDAC
is likely rise in the next few decades, underlining the importance of
this contention.
Currently, the management of patients with PDAC differs widely
across Europe. While the treatment of patients within specialist
centres and management by multidisciplinary teams (MDTs) has
been the norm in some countries like the UK and the Netherlands
for more than a decade, in others, MDT management is not
enforced and treatment within specialist centres relies on patients'
proximity to these hospitals. Such variations can impact substan-
tially on both access to clinical trials and outcome; standardization
of patient management across Europe could well improve the
outlook for individuals with PDAC. A further factor that may
improve outcomes for patients with PDAC is the introduction of
palliative care soon after diagnosis, since this approach had been
shown to result in improvement in both quality of life and survival
in patients with non-small cell lung cancer [138,139]. Additional
approaches aimed at improving outcomes in PDAC are listed in
Table 4.
Summary
PDAC has the poorest survival rate among common cancers [3],
which is primarily attributed to the advanced stage of disease in
most patients at diagnosis. Therefore, there is an urgent need to
discover accurate markers of pre-invasive pancreatic neoplasms in
order to facilitate prediction of cancer risk and to help diagnose the
disease at an earlier stage, along with the identiﬁcation of an ac-
curate, low-cost screening test for early PDAC for use in clinical
practice. The development of more effective therapies is also crucial
in PDAC, since new advances have been limited in recent years and
treatment of the disease remains a major challenge. This article
proposes a number of strategies that may help to accelerate prog-
ress in treating patients with the condition. It is hoped that incor-
poration of some of these approaches will go some way to
improving quality of life and survival for individuals with this
devastating disease.
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